Dongyun Zhang Selected Research

isorhapontigenin

7/2016	Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis.
1/2016	SESN2/sestrin 2 induction-mediated autophagy and inhibitory effect of isorhapontigenin (ISO) on human bladder cancers.
5/2014	Isorhapontigenin (ISO) inhibited cell transformation by inducing G0/G1 phase arrest via increasing MKP-1 mRNA Stability.
10/2012	The Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by down-regulating overexpression of antiapoptotic protein XIAP.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dongyun Zhang Research Topics

Disease

44	Neoplasms (Cancer) 05/2022 - 10/2005
11	Carcinogenesis 06/2017 - 07/2006
8	Urinary Bladder Neoplasms (Bladder Cancer) 12/2021 - 10/2012
4	Pituitary ACTH Hypersecretion 04/2021 - 01/2016
3	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 01/2019
3	Skin Neoplasms (Skin Cancer) 01/2008 - 04/2006
3	Inflammation (Inflammations) 09/2007 - 07/2006
2	Neoplasm Metastasis (Metastasis) 12/2019 - 04/2012
2	Hypoxia (Hypoxemia) 10/2012 - 01/2010
2	Lung Neoplasms (Lung Cancer) 06/2009 - 08/2006
1	Infections 06/2022
1	Vascular Diseases (Vascular Disease) 03/2022
1	Coronary Disease (Coronary Heart Disease) 03/2022
1	Fibrosis (Cirrhosis) 02/2022
1	Myocardial Infarction 02/2022
1	Glucose Metabolism Disorders 01/2022
1	Central Nervous System Diseases (CNS Diseases) 01/2022
1	Hyperinsulinism (Hyperinsulinemia) 01/2022
1	Spinal Cord Injuries (Spinal Cord Injury) 01/2022
1	Neuroinflammatory Diseases 01/2022
1	Obesity 01/2022
1	Cicatrix (Scar) 01/2022
1	Adenoma (Adenomas) 11/2021
1	Pituitary Neoplasms (Pituitary Adenoma) 04/2021
1	ACTH-Secreting Pituitary Adenoma 04/2021
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2020
1	Infarction (Infarctions) 01/2020
1	Neurologic Manifestations (Neurological Manifestations) 01/2020
1	Brain Infarction 01/2020
1	Neuroblastoma 03/2019
1	Prolactinoma (Prolactinomas) 01/2019
1	Neurocytoma 01/2019
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2019
1	Residual Neoplasm 01/2019

Drug/Important Bio-Agent (IBA)

11	Proteins (Proteins, Gene)FDA Link 12/2021 - 11/2006
9	arseniteIBA 09/2013 - 10/2005
5	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 05/2022 - 01/2016
5	Adrenocorticotropic Hormone (ACTH)FDA Link 11/2021 - 01/2016
5	Messenger RNA (mRNA)IBA 12/2019 - 02/2015
5	CarcinogensIBA 07/2016 - 01/2006
4	isorhapontigeninIBA 07/2016 - 10/2012
4	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2016 - 01/2006
4	Cyclin D1IBA 05/2014 - 01/2009
4	X-Linked Inhibitor of Apoptosis ProteinIBA 07/2013 - 05/2011
3	Transcription Factors (Transcription Factor)IBA 01/2022 - 07/2006
3	Phosphotransferases (Kinase)IBA 01/2021 - 10/2018
3	rho-Specific Guanine Nucleotide Dissociation InhibitorsIBA 04/2012 - 05/2011
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 09/2007 - 07/2006
2	Hormones (Hormone)IBA 05/2022 - 10/2016
2	RNA (Ribonucleic Acid)IBA 05/2022 - 04/2021
2	CytokinesIBA 01/2022 - 07/2006
2	CorticosteroneIBA 01/2021 - 10/2016
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 01/2019
2	Liposomes (Liposome)IBA 01/2020 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 11/2019 - 10/2016
2	LigandsIBA 01/2019 - 01/2019
2	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2019 - 01/2019
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2019 - 10/2018
2	Leucine-Rich Repeat ProteinsIBA 01/2019 - 10/2018
2	Member 2 Group C Nuclear Receptor Subfamily 2IBA 10/2016 - 01/2016
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 09/2013 - 08/2010
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 07/2013 - 01/2012
2	Biological ProductsIBA 07/2013 - 05/2011
2	ArsenicIBA 02/2009 - 04/2007
2	NickelIBA 01/2009 - 12/2006
2	Small Interfering RNA (siRNA)IBA 10/2007 - 11/2006
2	NF-kappa B (NF-kB)IBA 01/2007 - 11/2006
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2006 - 01/2006
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 06/2022
1	Peptide Hydrolases (Proteases)FDA Link 05/2022
1	Remifentanil (Ultiva)FDA Link 02/2022
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2022
1	LeptinIBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 01/2022
1	Hydrocortisone (Cortisol)FDA LinkGeneric 04/2021
1	Small Cytoplasmic RNAIBA 04/2021
1	CUDC-907IBA 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021
1	AntigensIBA 01/2021
1	Histone Deacetylase InhibitorsIBA 01/2021
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2021
1	4-nitrobenzylthioinosineIBA 01/2020
1	Equilibrative Nucleoside Transporter 1IBA 01/2020
1	Matrix Metalloproteinases (MMPs)IBA 12/2019
1	Estrogen Receptor betaIBA 11/2019
1	Estrogen Receptor alphaIBA 11/2019
1	Chromogranin AIBA 03/2019
1	Everolimus FDA Link 01/2019
1	ProlactinIBA 01/2019
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2019
1	Octreotide (Sandostatin)FDA LinkGeneric 01/2019
1	Dopamine Agonists (Dopamine Agonist)IBA 01/2019

Therapy/Procedure

12	Therapeutics 02/2022 - 10/2016
1	Replacement Arthroplasty 06/2022
1	Activities of Daily Living (ADL) 03/2022
1	Dentures 03/2022
1	Vagus Nerve Stimulation 01/2022
1	Drug Therapy (Chemotherapy) 01/2021
1	Intraperitoneal Injections 01/2020
1	Radiotherapy 01/2019